Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia

Chris L. Pashos, PhD, Christopher R Flowers, MD, Mark Weiss, MD, Nicole Lamanna, MD, Charles M Farber, MD, PhD, Thomas J. Kipps, M.D., Ph.D, Susan Lerner, MS, BA, Neil Kay, MD, Jeff Porte Sharman, MD, David L. Grinblatt, MD, Ian W. Flinn, MD, PhD, Mark Kozloff, MD, Arlene S Swern, PhD, Zeba M. Kahn, Ph.D, Thomas K. Street, RPh, Kristen A Sullivan, MBA, Gale Harding, MA, Michael J Keating, MD

Blood (2011) 118 (21): 2085.

https://doi.org/10.1182/blood.V118.21.2085.2085

Published: 2011

Journal Articles

A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL,

William G. Wierda, MD, PhD, Kumudha Balakrishnan, Alessandra Ferrajoli, MD, Tapan Kadia, Jorge E. Cortes, Susan O'Brien, MD, Jan A. Burger, MD, PhD, Francesco Paolo Tambaro, MD, PhD, Annette Jalayer, RN, Susan Lerner, MS, BA, Michael J Keating, MD, Varsha Gandhi, PhD

Blood (2011) 118 (21): 3901.

https://doi.org/10.1182/blood.V118.21.3901.3901

Published: 2011

Journal Articles

Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyclosphosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL,

William G. Wierda, MD, PhD, Susan O'Brien, MD, Alessandra Ferrajoli, MD, Charles Asa Koller, MD, Jan A. Burger, MD, PhD, Stefan Faderl, MD, Guillermo Garcia-Manero, Tapan Kadia, Susan Lerner, MS, BA, Michael J Keating, MD

Blood (2011) 118 (21): 3902.

https://doi.org/10.1182/blood.V118.21.3902.3902

Published: 2011

Journal Articles

Initial Experience with Lenalidomide As Consolidation Treatment in Patients with Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy,

Jenny V. Pozadzides, MD, Michael J Keating, MD, William G. Wierda, Susan O'Brien, MD, Jan A. Burger, MD, PhD, Jeffrey L. Jorgensen, MD, Steliana Calin, MD, SA Wang, MD, Susan Lerner, MS, BA, Alessandra Ferrajoli, MD

Blood (2011) 118 (21): 3907.

https://doi.org/10.1182/blood.V118.21.3907.3907

Published: 2011

Journal Articles

Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Xavier C Badoux, MBBS, Michael J Keating, MD, Susan O'Brien, MD, William G. Wierda, MD, PhD, Stefan Faderl, MD, Zeev Estrov, Manolo Pasia, BSN, Susan Lerner, MS, BA, Rachel L Sargent, MD, Hagop M. Kantarjian, MD, Alessandra Ferrajoli, MD

Blood (2011) 118 (21): 980.

https://doi.org/10.1182/blood.V118.21.980.980

Published: 2011

Journal Articles

Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC)

Francesco Paolo Tambaro, MD, PhD, Guillermo Garcia-Manero, Stefan Faderl, MD, Susan O'Brien, MD, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Long Xuan Trinh, Susan Lerner, MS, BA, Hagop M. Kantarjian, Michael J Keating, MD, William G. Wierda, MD, PhD

Blood (2011) 118 (21): 981.

https://doi.org/10.1182/blood.V118.21.981.981

Published: 2011

Journal Articles

Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia

Chris L. Pashos, PhD, Christopher R Flowers, MD, Mark Weiss, MD, Nicole Lamanna, MD, Charles M Farber, MD, PhD, Thomas J. Kipps, M.D., Ph.D, Susan Lerner, MS, BA, Neil Kay, MD, Jeff Porte Sharman, MD, David L. Grinblatt, MD, Ian W. Flinn, MD, PhD, Mark Kozloff, MD, Arlene S Swern, PhD, Zeba M. Kahn, Ph.D, Thomas K. Street, RPh, Gale Harding, MA, Kristen A Sullivan, MBA, Michael J Keating, MD

Blood (2011) 118 (21): 4591.

https://doi.org/10.1182/blood.V118.21.4591.4591

Published: 2011

Journal Articles

Retrospective Analysis of the Experience with Rituximab and Methylprednisone In Elderly Patients with CLL

Xavier Badoux, MD, Ali M Al-Ameri, Susan O'Brien, MD, William G. Wierda, MD, PhD, Jan A. Burger, MD, PhD, Stefan Faderl, MD, Zeev Estrov, MD, Susan Lerner, MS, BA, Michael J Keating, MD, Alessandra Ferrajoli, MD

Blood (2010) 116 (21): 4636.

https://doi.org/10.1182/blood.V116.21.4636.4636

Published: 2010

Journal Articles

The Combination of Lenalidomide and Rituximab Induces Complete and Partial Responses In Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

Alessandra Ferrajoli, MD, Xavier Badoux, MD, Susan O'Brien, William G. Wierda, MD, PhD, Stefan Faderl, MD, Zeev Estrov, MD, Manolo Pasia, BSN, Susan Lerner, MS, BA, Hagop Kantarjian, MD, Michael J Keating, MD

Blood (2010) 116 (21): 1395.

https://doi.org/10.1182/blood.V116.21.1395.1395

Published: 2010

Journal Articles

Circulating CD52 and CD20 Levels Predict for Progression and Survival in Patients with CLL Treated with Fludarabine (F), Cyclophosphamide (C), and Rituximab (FCR).

Gheath Alatrash, DO, PhD, Michael J. Keating, MBBS, Susan O’Brien, MD, Xuemei Wang, MS, Taghi Manshouri, MS,BS, Stefan Faderl, MD, Alessadra Ferrajoli, MD, Hagop M. Kantarjian, MD, Susan Lerner, MS,BA, William G. Wierda, MD,PhD

Blood (2006) 108 (11): 2330.

https://doi.org/10.1182/blood.V108.11.2330.2330

Published: 2006

Journal Articles

Clinical Outcomes and Prognostic Factors in Patients with Richter’s Syndrome Treated with Chemotherapy and/or Immunotherapy with or without Stem Cell Transplantation.

Apostolia-Maria Tsimberidou, MD, PhD, Susan O’Brien, MD, BA, Issa Khouri, MD, BS, Francis J. Giles, MD, Hagop M. Kantarjian, MD, Sijin Wen, MS, Susan C. Smith, BS, Susan Lerner, MS, BA, Emil J. Freireich, MD, BS, Michael J. Keating, MD

Blood (2005) 106 (11): 2097.

https://doi.org/10.1182/blood.V106.11.2097.2097

Published: 2005

Journal Articles

Outcomes in Patients with Splenic Marginal Zone Lymphoma or Marginal Zone Leukemia/Lymphoma Treated with Immunotherapy, Chemoimmunotherapy, or Chemotherapy.

Apostolia-Maria Tsimberidou, MD, PhD, Daniel Catovsky, MD, Ellen Schlette, MD, Susan O’Brien, MD, BA, Hagop Kantarjian, MD, William G. Wierda, MD, PhD, Sijin Wen, MS, Susan Lerner, MS, BA, Michael J. Keating, MD

Blood (2005) 106 (11): 922.

https://doi.org/10.1182/blood.V106.11.922.922

Published: 2005

Journal Articles

Transformation of Chronic Lymphocytic Leukemia into Hodgkin’s Disease The M D Anderson Cancer Center Experience.

Apostolia-Maria Tsimberidou, MD, PhD, Susan O’Brien, MD, BA, Hagop Kantarjian, MD, Charles Koller, MD, BA, Fredrick Hagemeister, MD, BA, Luis Fayad, MD, Susan Lerner, MS, BA, Michael J. Keating, MD

Blood (2005) 106 (11): 976.

https://doi.org/10.1182/blood.V106.11.976.976

Published: 2005

NARROW

Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia

A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL,

Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyclosphosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL,

Initial Experience with Lenalidomide As Consolidation Treatment in Patients with Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy,

Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC)

Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia

Retrospective Analysis of the Experience with Rituximab and Methylprednisone In Elderly Patients with CLL

The Combination of Lenalidomide and Rituximab Induces Complete and Partial Responses In Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

Circulating CD52 and CD20 Levels Predict for Progression and Survival in Patients with CLL Treated with Fludarabine (F), Cyclophosphamide (C), and Rituximab (FCR).

Clinical Outcomes and Prognostic Factors in Patients with Richter’s Syndrome Treated with Chemotherapy and/or Immunotherapy with or without Stem Cell Transplantation.

Outcomes in Patients with Splenic Marginal Zone Lymphoma or Marginal Zone Leukemia/Lymphoma Treated with Immunotherapy, Chemoimmunotherapy, or Chemotherapy.

Transformation of Chronic Lymphocytic Leukemia into Hodgkin’s Disease The M D Anderson Cancer Center Experience.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only